Sofinnova leads €11m fundraising for DNA Script

Existing investors Sofinnova, Kurma and Idinvest were joined by Illumina Ventures and Merck Ventures in the series-A.

The funds raised will allow DNA Script to strengthen its enzymatic technology and nucleotide chemistry platform in order to manufacture oligonucleotides in a faster, cleaner and more affordable way compared with current market standards.

Sofinnova now holds 10 industrial biotech companies after launching a new strategy to target the sector in 2009. It invests in the space through its €22.5m Green Seed fund and its €106m Sofinnova IB I fund. 

Company
Founded in 2014 in Paris, DNA Script manufactures synthetic nucleic acids using enzymatic technology. According to the company, its technology has the potential to be used in the development of new therapeutics, sustainable chemical production, improved crops and data storage.

People
Sofinnova Partners – Joško Bobanović (partner).
DNA Script – Thomas Ybert (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• France
• Sofinnova Partners
• IDInvest Partners (AGF Private Equity)
• Venture